Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155192 · ClinicalTrials.gov registry record
An Exploratory Genetic Study in Participants With Psoriasis
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 712
- Enrollment target
NCT02155192: Completed study, sponsored by Janssen Research & Development.
NCT02155192 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 712 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02155192 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 712 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the association between genetic factors and response to treatment (guselkumab, ustekinumab, adalimumab, or etanercept) and psoriasis (scaly skin rash).
Primary Outcome
Participants with clinical response from previous studies will be evaluated for the association with genetic factors (for example, human leukocyte antigen \[HLA\], Cw6 allele). Clinical response in previous studies were evaluated by psoriasis area and severity index (PASI) score: a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a participant's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determi
Interventions
- DRUG No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 712 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-09 |
What the finished NCT02155192 record still lists
NCT02155192 is an observational study that tracks outcomes without assigning an intervention. The registered 712 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT02155192 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02155192 about?
NCT02155192 is a clinical study titled "An Exploratory Genetic Study in Participants With Psoriasis". The purpose of this study is to evaluate the association between genetic factors and response to treatment (guselkumab, ustekinumab, adalimumab, or etanercept) and psoriasis (scaly skin rash).
What is the current status of trial NCT02155192?
This trial is currently completed. The enrollment target is 712 participants. The study started on 2014-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02155192?
The interventions under investigation include: No Intervention (DRUG).
Who is sponsoring clinical trial NCT02155192?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia